Last reviewed · How we verify

NCT05646810

Impact of Peripheral Afferent Input on Central Neuropathic Pain

Status unknown NA Last updated 12 December 2022
What this trial tests

NA trial testing Lidocaine (10 mg/ml) in Spinal Cord Injuries in 20 participants. Status unknown.

Timeline
1 December 2022
Primary endpoint
30 September 2023
31 December 2023

Quick facts

Lead sponsorUniversity of Aarhus
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposediagnostic
Enrollment20
Start date1 December 2022
Primary completion30 September 2023
Estimated completion31 December 2023

Drugs / interventions tested

Conditions studied

Sponsor

University of Aarhus

Who can join

18 and older, any sex, with Spinal Cord Injuries or Spinal Cord Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overarching aim of this study is to investigate the contribution of peripheral afferent input to spontaneous and evoked central neuropathic pain after a spinal cord lesion or disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Spinal Cord Injuries

Currently open trials in the same condition.

Other University of Aarhus trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05646810.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing